Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9985 to 9996 of 108427 entries
Sorted by: Best Match Show Resources per page
WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH.

Therapeutic advances in urology

Kirschner-Hermanns R, Funk P, Leistner N.
PMID: 31656534
Ther Adv Urol. 2019 Oct 11;11:1756287219879533. doi: 10.1177/1756287219879533. eCollection 2019.

INTRODUCTION: Lower urinary tract symptoms (LUTS) caused by prostatic enlargement are a common impairing condition in men aged 50 years and older. In the management of LUTS related to benign prostatic hyperplasia (BPH), medication, particularly by α-adrenoceptor antagonists, 5α-reductase...

Cite
Kirschner-Hermanns R, Funk P, Leistner N. WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH. Ther Adv Urol. 2019;11:1756287219879533doi: 10.1177/1756287219879533.
Kirschner-Hermanns, R., Funk, P., & Leistner, N. (2019). WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH. Therapeutic advances in urology, 111756287219879533. https://doi.org/10.1177/1756287219879533
Kirschner-Hermanns, Ruth, et al. "WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH." Therapeutic advances in urology vol. 11 (2019): 1756287219879533. doi: https://doi.org/10.1177/1756287219879533
Kirschner-Hermanns R, Funk P, Leistner N. WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH. Ther Adv Urol. 2019 Oct 11;11:1756287219879533. doi: 10.1177/1756287219879533. eCollection 2019. PMID: 31656534; PMCID: PMC6791037.
Copy Download .nbib Format: NLM
Recent advances in monoclonal antibody therapy in IBD: practical issues.

Frontline gastroenterology

Tamilarasan AG, Cunningham G, Irving PM, Samaan MA.
PMID: 31656567
Frontline Gastroenterol. 2019 Oct;10(4):409-416. doi: 10.1136/flgastro-2018-101054. Epub 2019 Jan 18.

The advent of monoclonal antibody therapies has revolutionised inflammatory bowel disease (IBD) treatment and delivered great benefits to patients. The optimal use of this class of drugs requires careful management and a clear understanding of their properties. In this...

Cite
Tamilarasan AG, Cunningham G, Irving PM, et al. Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline Gastroenterol. 2019;10(4):409-416doi: 10.1136/flgastro-2018-101054.
Tamilarasan, A. G., Cunningham, G., Irving, P. M., & Samaan, M. A. (2019). Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline gastroenterology, 10(4), 409-416. https://doi.org/10.1136/flgastro-2018-101054
Tamilarasan, Aravind Gokul, et al. "Recent advances in monoclonal antibody therapy in IBD: practical issues." Frontline gastroenterology vol. 10,4 (2019): 409-416. doi: https://doi.org/10.1136/flgastro-2018-101054
Tamilarasan AG, Cunningham G, Irving PM, Samaan MA. Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline Gastroenterol. 2019 Oct;10(4):409-416. doi: 10.1136/flgastro-2018-101054. Epub 2019 Jan 18. PMID: 31656567; PMCID: PMC6788124.
Copy Download .nbib Format: NLM
ATP-Charged Nanoclusters Enable Intracellular Protein Delivery and Activity Modulation for Cancer Theranostics.

iScience

Zhou Z, Zhang Q, Yang R, Wu H, Zhang M, Qian C, Chen X, Sun M.
PMID: 32059177
iScience. 2020 Feb 21;23(2):100872. doi: 10.1016/j.isci.2020.100872. Epub 2020 Jan 31.

Protein drugs own a large share in the market and hold great prospects for the treatment of many diseases. However, the available protein drugs are limited to the extracellular target, owing to the inefficient transduction and activity modulation of...

Cite
Zhou Z, Zhang Q, Yang R, et al. ATP-Charged Nanoclusters Enable Intracellular Protein Delivery and Activity Modulation for Cancer Theranostics. iScience. 2020;23(2):100872doi: 10.1016/j.isci.2020.100872.
Zhou, Z., Zhang, Q., Yang, R., Wu, H., Zhang, M., Qian, C., Chen, X., & Sun, M. (2020). ATP-Charged Nanoclusters Enable Intracellular Protein Delivery and Activity Modulation for Cancer Theranostics. iScience, 23(2), 100872. https://doi.org/10.1016/j.isci.2020.100872
Zhou, Zhanwei, et al. "ATP-Charged Nanoclusters Enable Intracellular Protein Delivery and Activity Modulation for Cancer Theranostics." iScience vol. 23,2 (2020): 100872. doi: https://doi.org/10.1016/j.isci.2020.100872
Zhou Z, Zhang Q, Yang R, Wu H, Zhang M, Qian C, Chen X, Sun M. ATP-Charged Nanoclusters Enable Intracellular Protein Delivery and Activity Modulation for Cancer Theranostics. iScience. 2020 Feb 21;23(2):100872. doi: 10.1016/j.isci.2020.100872. Epub 2020 Jan 31. PMID: 32059177; PMCID: PMC7016238.
Copy Download .nbib Format: NLM
Erectile Dysfunction/Impotence: An Update of Drugs, Drug Delivery/Management, and Approaches or Strategies.

Skinmed

Sehgal VN.
PMID: 31627787
Skinmed. 2019 Jul 01;17(4):256-259. eCollection 2019.

Erectile dysfunction/impotence, a universal phenomenon, is a type of sexual dysfunction, the incidence of which is unknown. Certainly, its management options has changing scenario, in particular, take cognizance of phosphodiesterase type 5 inhibitors being the pivot, the highlight of...

Cite
Sehgal VN. Erectile Dysfunction/Impotence: An Update of Drugs, Drug Delivery/Management, and Approaches or Strategies. Skinmed. 2019;17(4):256-259
Sehgal, V. N. (2019). Erectile Dysfunction/Impotence: An Update of Drugs, Drug Delivery/Management, and Approaches or Strategies. Skinmed, 17(4), 256-259.
Sehgal, Virendra N. "Erectile Dysfunction/Impotence: An Update of Drugs, Drug Delivery/Management, and Approaches or Strategies." Skinmed vol. 17,4 (2019): 256-259.
Sehgal VN. Erectile Dysfunction/Impotence: An Update of Drugs, Drug Delivery/Management, and Approaches or Strategies. Skinmed. 2019 Jul 01;17(4):256-259. eCollection 2019. PMID: 31627787.
Copy Download .nbib Format: NLM
Role of medicinal plants in the management of diabetes mellitus: a review.

3 Biotech

Bindu Jacob, Narendhirakannan R T.
PMID: 30555770
3 Biotech. 2019 Jan;9(1):4. doi: 10.1007/s13205-018-1528-0. Epub 2018 Dec 12.

Medicinal plants have a vast potential in the treatment of various ailments due to the presence of therapeutically important phytochemicals. Diabetes is a serious metabolic disorder and several marketed medications are available to alleviate the symptoms of diabetes. However,...

Cite
Bindu Jacob, Narendhirakannan R T. Role of medicinal plants in the management of diabetes mellitus: a review. 3 Biotech. 2018;9(1):4doi: 10.1007/s13205-018-1528-0.
Bindu Jacob, & Narendhirakannan R T. (2019). Role of medicinal plants in the management of diabetes mellitus: a review. 3 Biotech, 9(1), 4. https://doi.org/10.1007/s13205-018-1528-0
Bindu Jacob, and Narendhirakannan R T. "Role of medicinal plants in the management of diabetes mellitus: a review." 3 Biotech vol. 9,1 (2019): 4. doi: https://doi.org/10.1007/s13205-018-1528-0
Bindu Jacob, Narendhirakannan R T. Role of medicinal plants in the management of diabetes mellitus: a review. 3 Biotech. 2019 Jan;9(1):4. doi: 10.1007/s13205-018-1528-0. Epub 2018 Dec 12. PMID: 30555770; PMCID: PMC6291410.
Copy Download .nbib Format: NLM
[Replacement therapy for hypothyroidism with thyroid hormonal drugs: one or two hormones?].

Problemy endokrinologii

Morgunova ТВ, Fadeyev VV.
PMID: 31627540
Probl Endokrinol (Mosk). 2005 Feb 15;51(1):53-56. doi: 10.14341/probl200551153-56.

In recent years, along with a large number of works devoted to the problem of subclinical hypothyroidism, the first studies have appeared that raise the problem that was actively discussed in the 70s at the current methodological level -...

Cite
Morgunova ТВ, Fadeyev VV. [Replacement therapy for hypothyroidism with thyroid hormonal drugs: one or two hormones?]. Probl Endokrinol (Mosk). 2005;51(1):53-56doi: 10.14341/probl200551153-56.
Morgunova, �. �. �. �., & Fadeyev, V. V. (2005). [Replacement therapy for hypothyroidism with thyroid hormonal drugs: one or two hormones?]. Problemy endokrinologii, 51(1), 53-56. https://doi.org/10.14341/probl200551153-56
Morgunova, Т В, and Fadeyev, V V. "[Replacement therapy for hypothyroidism with thyroid hormonal drugs: one or two hormones?]." Problemy endokrinologii vol. 51,1 (2005): 53-56. doi: https://doi.org/10.14341/probl200551153-56
Morgunova ТВ, Fadeyev VV. [Replacement therapy for hypothyroidism with thyroid hormonal drugs: one or two hormones?]. Probl Endokrinol (Mosk). 2005 Feb 15;51(1):53-56. doi: 10.14341/probl200551153-56. Russian. PMID: 31627540.
Copy Download .nbib Format: NLM
Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines .

Evidence-based complementary and alternative medicine : eCAM

Watanabe K.
PMID: 30584454
Evid Based Complement Alternat Med. 2018 Nov 21;2018:6058181. doi: 10.1155/2018/6058181. eCollection 2018.

Influenza virus infections are a serious public health concern throughout the world. Emergence of viral resistance to the currently approved anti-influenza drugs warrants the development of new antiviral agents. Japanese herbal medicines called Kampo are very commonly used as...

Cite
Watanabe K. Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines . Evid Based Complement Alternat Med. 2018;2018:6058181doi: 10.1155/2018/6058181.
Watanabe, K. (2018). Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines . Evidence-based complementary and alternative medicine : eCAM, 20186058181. https://doi.org/10.1155/2018/6058181
Watanabe, Ken. "Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines ." Evidence-based complementary and alternative medicine : eCAM vol. 2018 (2018): 6058181. doi: https://doi.org/10.1155/2018/6058181
Watanabe K. Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines . Evid Based Complement Alternat Med. 2018 Nov 21;2018:6058181. doi: 10.1155/2018/6058181. eCollection 2018. PMID: 30584454; PMCID: PMC6280228.
Copy Download .nbib Format: NLM
Comparison of the Analgesic Efficacy of a Single Dose of Epidural Dexmedetomidine versus Fentanyl as an Adjuvant to Bupivacaine in Abdominal Surgery.

Anesthesia, essays and researches

Sekhar DP, Kumar L, Kesavan R, Purushottaman S, Mohammed ZU, Rajan S.
PMID: 31602062
Anesth Essays Res. 2019 Jul-Sep;13(3):465-470. doi: 10.4103/aer.AER_102_19.

BACKGROUND: Fentanyl as an epidural additive act on spinal opioid receptors, while dexmedetomidine has selective alpha-2 receptor agonist action enhancing analgesic effects.AIMS: We aimed to compare the postoperative analgesic efficacy of single doses of dexmedetomidine against fentanyl as epidural...

Cite
Sekhar DP, Kumar L, Kesavan R, et al. Comparison of the Analgesic Efficacy of a Single Dose of Epidural Dexmedetomidine versus Fentanyl as an Adjuvant to Bupivacaine in Abdominal Surgery. Anesth Essays Res. 2019;13(3):465-470doi: 10.4103/aer.AER_102_19.
Sekhar, D. P., Kumar, L., Kesavan, R., Purushottaman, S., Mohammed, Z. U., & Rajan, S. (2019). Comparison of the Analgesic Efficacy of a Single Dose of Epidural Dexmedetomidine versus Fentanyl as an Adjuvant to Bupivacaine in Abdominal Surgery. Anesthesia, essays and researches, 13(3), 465-470. https://doi.org/10.4103/aer.AER_102_19
Sekhar, Durga Prasad, et al. "Comparison of the Analgesic Efficacy of a Single Dose of Epidural Dexmedetomidine versus Fentanyl as an Adjuvant to Bupivacaine in Abdominal Surgery." Anesthesia, essays and researches vol. 13,3 (2019): 465-470. doi: https://doi.org/10.4103/aer.AER_102_19
Sekhar DP, Kumar L, Kesavan R, Purushottaman S, Mohammed ZU, Rajan S. Comparison of the Analgesic Efficacy of a Single Dose of Epidural Dexmedetomidine versus Fentanyl as an Adjuvant to Bupivacaine in Abdominal Surgery. Anesth Essays Res. 2019 Jul-Sep;13(3):465-470. doi: 10.4103/aer.AER_102_19. PMID: 31602062; PMCID: PMC6775832.
Copy Download .nbib Format: NLM
Evaluation and Management of Patients with Diabetes and Hearing Loss.

Seminars in hearing

Spankovich C, Yerraguntla K.
PMID: 31602094
Semin Hear. 2019 Nov;40(4):308-314. doi: 10.1055/s-0039-1697644. Epub 2019 Oct 09.

Diabetes mellitus is a significant risk factor for acquired hearing loss and tinnitus. Persons with diabetes (PWD) may present with hearing loss symptoms earlier in life than those without diabetes. Furthermore, diabetes may exacerbate risk for hearing loss related...

Cite
Spankovich C, Yerraguntla K. Evaluation and Management of Patients with Diabetes and Hearing Loss. Semin Hear. 2019;40(4):308-314doi: 10.1055/s-0039-1697644.
Spankovich, C., & Yerraguntla, K. (2019). Evaluation and Management of Patients with Diabetes and Hearing Loss. Seminars in hearing, 40(4), 308-314. https://doi.org/10.1055/s-0039-1697644
Spankovich, Christopher, and Yerraguntla, Krishna. "Evaluation and Management of Patients with Diabetes and Hearing Loss." Seminars in hearing vol. 40,4 (2019): 308-314. doi: https://doi.org/10.1055/s-0039-1697644
Spankovich C, Yerraguntla K. Evaluation and Management of Patients with Diabetes and Hearing Loss. Semin Hear. 2019 Nov;40(4):308-314. doi: 10.1055/s-0039-1697644. Epub 2019 Oct 09. PMID: 31602094; PMCID: PMC6785337.
Copy Download .nbib Format: NLM
Redox-Mediated Mechanism of Chemoresistance in Cancer Cells.

Antioxidants (Basel, Switzerland)

Kim EK, Jang M, Song MJ, Kim D, Kim Y, Jang HH.
PMID: 31658599
Antioxidants (Basel). 2019 Oct 10;8(10). doi: 10.3390/antiox8100471.

Cellular reactive oxygen species (ROS) status is stabilized by a balance of ROS generation and elimination called redox homeostasis. ROS is increased by activation of endoplasmic reticulum stress, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family members and adenosine triphosphate...

Cite
Kim EK, Jang M, Song MJ, et al. Redox-Mediated Mechanism of Chemoresistance in Cancer Cells. Antioxidants (Basel). 2019;8(10)doi: 10.3390/antiox8100471.
Kim, E. K., Jang, M., Song, M. J., Kim, D., Kim, Y., & Jang, H. H. (2019). Redox-Mediated Mechanism of Chemoresistance in Cancer Cells. Antioxidants (Basel, Switzerland), 8(10), . https://doi.org/10.3390/antiox8100471
Kim, Eun-Kyung, et al. "Redox-Mediated Mechanism of Chemoresistance in Cancer Cells." Antioxidants (Basel, Switzerland) vol. 8,10 (2019). doi: https://doi.org/10.3390/antiox8100471
Kim EK, Jang M, Song MJ, Kim D, Kim Y, Jang HH. Redox-Mediated Mechanism of Chemoresistance in Cancer Cells. Antioxidants (Basel). 2019 Oct 10;8(10). doi: 10.3390/antiox8100471. PMID: 31658599; PMCID: PMC6826977.
Copy Download .nbib Format: NLM
Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?.

Pediatric nephrology (Berlin, Germany)

Seeman T, Feber J.
PMID: 32060819
Pediatr Nephrol. 2021 Mar;36(3):539-549. doi: 10.1007/s00467-020-04485-8. Epub 2020 Feb 14.

Arterial hypertension in renal transplant recipients warrants antihypertensive treatment. The preferable choice of antihypertensives that should be used in patients after kidney transplantation remains a matter of debate; however, calcium channel blockers (CCB) and angiotensin-converting enzyme inhibitors (ACEI) are...

Cite
Seeman T, Feber J. Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?. Pediatr Nephrol. 2020;36(3):539-549doi: 10.1007/s00467-020-04485-8.
Seeman, T., & Feber, J. (2021). Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?. Pediatric nephrology (Berlin, Germany), 36(3), 539-549. https://doi.org/10.1007/s00467-020-04485-8
Seeman, Tomáš, and Feber, Janusz. "Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?." Pediatric nephrology (Berlin, Germany) vol. 36,3 (2021): 539-549. doi: https://doi.org/10.1007/s00467-020-04485-8
Seeman T, Feber J. Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?. Pediatr Nephrol. 2021 Mar;36(3):539-549. doi: 10.1007/s00467-020-04485-8. Epub 2020 Feb 14. PMID: 32060819.
Copy Download .nbib Format: NLM
Terahertz Spectroscopy and Imaging: A Cutting-Edge Method for Diagnosing Digestive Cancers.

Materials (Basel, Switzerland)

Danciu M, Alexa-Stratulat T, Stefanescu C, Dodi G, Tamba BI, Mihai CT, Stanciu GD, Luca A, Spiridon IA, Ungureanu LB, Ianole V, Ciortescu I, Mihai C, Stefanescu G, Chirilă I, Ciobanu R, Drug VL.
PMID: 31075912
Materials (Basel). 2019 May 09;12(9). doi: 10.3390/ma12091519.

The Terahertz's wavelength is located between the microwave and the infrared region of the electromagnetic spectrum. Because it is non-ionizing and non-invasive, Terahertz (THz)-based detection represents a very attractive tool for repeated assessments, patient monitoring, and follow-up. Cancer acts...

Cite
Danciu M, Alexa-Stratulat T, Stefanescu C, et al. Terahertz Spectroscopy and Imaging: A Cutting-Edge Method for Diagnosing Digestive Cancers. Materials (Basel). 2019;12(9)doi: 10.3390/ma12091519.
Danciu, M., Alexa-Stratulat, T., Stefanescu, C., Dodi, G., Tamba, B. I., Mihai, C. T., Stanciu, G. D., Luca, A., Spiridon, I. A., Ungureanu, L. B., Ianole, V., Ciortescu, I., Mihai, C., Stefanescu, G., Chirilă, I., Ciobanu, R., & Drug, V. L. (2019). Terahertz Spectroscopy and Imaging: A Cutting-Edge Method for Diagnosing Digestive Cancers. Materials (Basel, Switzerland), 12(9), . https://doi.org/10.3390/ma12091519
Danciu, Mihai, et al. "Terahertz Spectroscopy and Imaging: A Cutting-Edge Method for Diagnosing Digestive Cancers." Materials (Basel, Switzerland) vol. 12,9 (2019). doi: https://doi.org/10.3390/ma12091519
Danciu M, Alexa-Stratulat T, Stefanescu C, Dodi G, Tamba BI, Mihai CT, Stanciu GD, Luca A, Spiridon IA, Ungureanu LB, Ianole V, Ciortescu I, Mihai C, Stefanescu G, Chirilă I, Ciobanu R, Drug VL. Terahertz Spectroscopy and Imaging: A Cutting-Edge Method for Diagnosing Digestive Cancers. Materials (Basel). 2019 May 09;12(9). doi: 10.3390/ma12091519. PMID: 31075912; PMCID: PMC6539301.
Copy Download .nbib Format: NLM
Showing 9985 to 9996 of 108427 entries